1. Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

    Journal of medicinal and pharmaceutical chemistry 58(4):1929 (2015) PMID 25625541

    Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand bin...
  2. Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

    Journal of medicinal and pharmaceutical chemistry 58(4):1929 (2015) PMID 25625541

    Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand bin...
  3. Squamous Intraepithelial Lesions in Cervical Tissue Samples of Limited Adequacy and Insufficient for Grading as Low or High Grade: Outcome, Clinico-Pathological Correlates, and Predictive Role of p16INK4a and Ki67 Biomarker Staining.

    Journal of Lower Genital Tract Disease 19(1):35 (2015) PMID 24859844

    Cervical tissue samples of limited adequacy but with pathological features of squamous intraepithelial lesions (SIL) may not be gradable and result in a diagnosis of ungraded SIL (SILQ). SILQ outcome, clinico-pathological correlates, and the predictive role of biomarker staining are unknown. Amo...
  4. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.

    PLoS ONE 10(7):e0132745 (2015) PMID 26192408 PMCID PMC4508028

    E1697 was a phase III trial of adjuvant interferon (IFN)-α2b for one month (Arm B) versus observation (Arm A) in patients with resected melanoma at intermediate risk. We evaluated the levels of candidate serum cytokines, the HLA genotype, polymorphisms of CTLA4 and FOXP3 genes and the developmen...
  5. Squamous Intraepithelial Lesions in Cervical Tissue Samples of Limited Adequacy and Insufficient for Grading as Low or High Grade: Outcome, Clinico-Pathological Correlates, and Predictive Role of p16INK4a and Ki67 Biomarker Staining.

    Journal of Lower Genital Tract Disease 19(1):35 (2015) PMID 24859844

    Cervical tissue samples of limited adequacy but with pathological features of squamous intraepithelial lesions (SIL) may not be gradable and result in a diagnosis of ungraded SIL (SILQ). SILQ outcome, clinico-pathological correlates, and the predictive role of biomarker staining are unknown. Amo...
  6. Squamous intraepithelial lesions in cervical tissue samples of limited adequacy and insufficient for grading as low or high grade: outcome, clinico-pathological correlates, and predictive role of p16INK4a and Ki67 biomarker staining.

    Journal of Lower Genital Tract Disease 19(1):35 (2015) PMID 24859844

    Cervical tissue samples of limited adequacy but with pathological features of squamous intraepithelial lesions (SIL) may not be gradable and result in a diagnosis of ungraded SIL (SILQ). SILQ outcome, clinico-pathological correlates, and the predictive role of biomarker staining are unknown. Amo...
  7. Evidence for stabilizing selection on codon usage in chromosomal rearrangements of Drosophila pseudoobscura.

    G3: Genes, Genomes, Genetics 4(12):2433 (2014) PMID 25326424 PMCID PMC4267939

    There has been a renewed interest in investigating the role of stabilizing selection acting on genome-wide traits such as codon usage bias. Codon bias, when synonymous codons are used at unequal frequencies, occurs in a wide variety of taxa. Standard evolutionary models explain the maintenance o...
  8. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

    JAMA 312(17):1744 (2014) PMID 25369488

    Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in preclinical ...
  9. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

    JAMA 312(17):1744 (2014) PMID 25369488

    Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in preclinical ...
  10. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

    JAMA 312(17):1744 (2014) PMID 25369488 PMCID PMC4336189

    Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in preclinical ...
  11. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

    JAMA 312(17):1744 (2014) PMID 25369488 PMCID PMC4336189

    Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in preclinical ...
  12. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

    JAMA 312(17):1744 (2014) PMID 25369488 PMCID PMC4336189

    Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in preclinical ...
  13. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

    JAMA 312(17):1744 (2014) PMID 25369488

    Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in preclinical ...
  14. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

    JAMA 312(17):1744 (2014) PMID 25369488

    Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in preclinical ...
  15. A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.

    Journal of Translational Medicine 12:19 (2014) PMID 24457057 PMCID PMC3909384

    E1694 tested GM2-KLH-QS21 vaccine versus high-dose interferon-α2b (HDI) as adjuvant therapy for operable stage IIB-III melanoma. We tested banked serum specimens from patients in the vaccine arm of E1694 for prognostic biomarkers. Aushon Multiplex Platform was used to quantitate baseline serum l...
  16. Evidence for Stabilizing Selection on Codon Usage in Chromosomal Rearrangements of Drosophila pseudoobscura.

    G3: Genes, Genomes, Genetics 4(12):2433 (2014) PMID 25326424

    There has been a renewed interest in investigating the role of stabilizing selection acting on genome-wide traits such as codon usage bias. Codon bias, when synonymous codons are used at unequal frequencies, occurs in a wide variety of taxa. Standard evolutionary models explain the maintenance o...
  17. Evidence for Stabilizing Selection on Codon Usage in Chromosomal Rearrangements of Drosophila pseudoobscura.

    G3: Genes, Genomes, Genetics 4(12):2433 (2014) PMID 25326424 PMCID PMC4267939

    There has been a renewed interest in investigating the role of stabilizing selection acting on genome-wide traits such as codon usage bias. Codon bias, when synonymous codons are used at unequal frequencies, occurs in a wide variety of taxa. Standard evolutionary models explain the maintenance o...
  18. Evidence for Stabilizing Selection on Codon Usage in Chromosomal Rearrangements of Drosophila pseudoobscura.

    G3: Genes, Genomes, Genetics 4(12):2433 (2014) PMID 25326424

    There has been a renewed interest in investigating the role of stabilizing selection acting on genome-wide traits such as codon usage bias. Codon bias, when synonymous codons are used at unequal frequencies, occurs in a wide variety of taxa. Standard evolutionary models explain the maintenance o...
  19. Evidence for Stabilizing Selection on Codon Usage in Chromosomal Rearrangements of Drosophila pseudoobscura.

    G3: Genes, Genomes, Genetics 4(12):2433 (2014) PMID 25326424 PMCID PMC4267939

    There has been a renewed interest in investigating the role of stabilizing selection acting on genome-wide traits such as codon usage bias. Codon bias, when synonymous codons are used at unequal frequencies, occurs in a wide variety of taxa. Standard evolutionary models explain the maintenance o...
  20. A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.

    Journal of Translational Medicine 12:19 (2014) PMID 24457057 PMCID PMC3909384

    E1694 tested GM2-KLH-QS21 vaccine versus high-dose interferon-α2b (HDI) as adjuvant therapy for operable stage IIB-III melanoma. We tested banked serum specimens from patients in the vaccine arm of E1694 for prognostic biomarkers. Aushon Multiplex Platform was used to quantitate baseline serum l...